Scholar Rock narrows path to FDA approval at Canaccord event

Biotechnology company Scholar Rock (SRRK) indicated its path to U.S. Food and Drug Administration (FDA) approval has narrowed, according to remarks made at the Canaccord Genuity Growth Conference on Tuesday.

The firm, which develops treatments for rare diseases, discussed the evolving regulatory landscape for its lead candidate, SRK-015, an experimental therapy for spinal muscular atrophy (SMA). Analysts and investors have closely monitored the drug’s progress amid concerns over trial design and endpoint efficacy.

Scholar Rock executives emphasized that while the therapeutic potential remains significant, the approval pathway has become more constrained due to recent FDA feedback. The company did not provide specific details on next steps but noted ongoing discussions with regulators to refine the submission strategy.

The biotech sector has faced increased scrutiny from the FDA in recent quarters, particularly for therapies targeting rare diseases where clinical endpoints can be difficult to measure. Scholar Rock’s shares have reflected investor uncertainty, with the stock declining in premarket trading following the conference remarks.

The company plans to submit additional data to the FDA in the coming months, though the timeline for a potential approval remains uncertain. Analysts suggest that any delays could impact commercialization plans and revenue projections for SRK-015.

Scholar Rock did not respond to requests for further comment beyond the conference presentation.